ACOG Updates Menopause Guidance, Expanding Treatment Options for Common Symptoms
Listen to the C2 Daily News report “ACOG Updates Menopause Guidance, Expanding Treatment Options for Common Symptoms” and answer 8 comprehension questions.
About this practice test
Listen to the C2 Daily News report “ACOG Updates Menopause Guidance, Expanding Treatment Options for Common Symptoms” and answer 8 comprehension questions.
What you’ll practice
Understanding detail
Follow specific information and examples.
Interpreting ideas
Identify main points and inferences.
Evaluating arguments
Assess claims, evidence, and limitations.
Study the questions and tasks
Work through the material below, or start the interactive practice above to complete an attempt. Try the exercises before opening any answer or transcript sections, then use them to review your work.
- Practice level
- C2. Try this level if you can follow the instructions and understand most of the language; choose an earlier level if you need more support.
- Question formats
- Single choice
How to approach this practice
Read the questions, then listen before opening the transcript. Notice names, numbers and any corrections the speaker makes.
News lesson for this practice
Read the complete article and use its text or audio alongside these exercises: ACOG Updates Menopause Guidance, Expanding Treatment Options for Common Symptoms.
ACOG Updates Menopause Guidance, Expanding Treatment Options for Common Symptoms
Read a transcript excerpt
The American College of Obstetricians and Gynecologists has updated its recommendations for treating symptoms associated with menopause, issuing its first revision since 2014. The guidance, released Thursday, focuses on matching treatment to particular symptoms rather than presenting menopause care as a single, uniform decision. ACOG recommends considering hormone replacement therapy alongside certain antidepressants, nonhormonal medicines, and other approaches for symptoms such as hot flashes, insomnia, and mood changes. Catherine Cansino,…
-
Question 1 · Single choice
Choose one answer.
When was ACOG's previous revision issued?
Return to the passage, recording or visual- 2002
- 2014
- 2023
- 2025
Check answers and explanations
- Answer
- 2014
The narration explicitly identifies 2014 as the previous revision date.
The American College of Obstetricians and Gynecologists has updated its recommendations for treating symptoms associated with menopause, issuing its first revision since 2014.
-
Question 2 · Single choice
Choose one answer.
Which symptoms are explicitly cited in the updated recommendations?
Return to the passage, recording or visual- Fever, nausea, and joint pain
- Hot flashes, insomnia, and mood changes
- Headaches, fatigue, and appetite loss
- Bleeding, seizures, and abdominal pain
Check answers and explanations
- Answer
- Hot flashes, insomnia, and mood changes
The recording names these three symptoms in its treatment discussion.
ACOG recommends considering hormone replacement therapy alongside certain antidepressants, nonhormonal medicines, and other approaches for symptoms such as hot flashes, insomnia, and mood changes.
-
Question 3 · Single choice
Choose one answer.
Who is identified as a co-author and committee chair?
Return to the passage, recording or visual- Robert Kauffman
- Catherine Cansino
- The FDA commissioner
- The Women’s Health Initiative director
Check answers and explanations
- Answer
- Catherine Cansino
The sentence directly attributes both roles to Catherine Cansino.
Catherine Cansino, chair of ACOG’s Committee on Clinical Practice Guidelines and a co-author of the recommendations, said the expanded range of treatments allows clinicians to take a more individualized approach.
-
Question 4 · Single choice
Choose one answer.
Which risks were associated with hormone therapy in the 2002 findings?
Return to the passage, recording or visual- Heart disease, breast cancer, stroke, and pulmonary embolism
- Insomnia, hot flashes, mood changes, and liver disease
- Endometrial cancer, pregnancy, bleeding, and infection
- Diabetes, osteoporosis, anemia, and migraine
Check answers and explanations
- Answer
- Heart disease, breast cancer, stroke, and pulmonary embolism
The narration lists four specific risks attributed to those findings.
In 2002, findings from the Women’s Health Initiative suggested that hormone replacement therapy could raise the risks of heart disease, breast cancer, stroke, and pulmonary embolism.
-
Question 5 · Single choice
Choose one answer.
What timing criterion is associated with the strongest recommendation for hormone therapy?
Return to the passage, recording or visual- Within two years of the first symptom
- Within five years of turning 60
- Within 10 years of the final menstrual period
- After ten years of nonhormonal treatment
Check answers and explanations
- Answer
- Within 10 years of the final menstrual period
The recommendation particularly concerns people within ten years of menopause onset.
According to the updated recommendations, hormone therapy is likely to be the most effective option for symptomatic people who have recently entered menopause, particularly those within 10 years of their final menstrual period or younger than 60.
-
Question 6 · Single choice
Choose one answer.
Which condition is named as a reason to avoid hormone therapy?
Return to the passage, recording or visual- Known or suspected pregnancy
- A history of mild insomnia
- Being younger than 60
- Experiencing perimenopause
Check answers and explanations
- Answer
- Known or suspected pregnancy
The sentence explicitly includes known or suspected pregnancy among contraindications.
The guidance lists undiagnosed abnormal genital bleeding, certain gynecologic cancers, blood clots, stroke, heart attack, liver disease, and known or suspected pregnancy among reasons to avoid it.
-
Question 7 · Single choice
Choose one answer.
What did the FDA approve Fezolinetant for in 2023?
Return to the passage, recording or visual- Mood changes
- Hot flashes
- Endometrial cancer
- Abnormal genital bleeding
Check answers and explanations
- Answer
- Hot flashes
The recording specifies that its approval concerned hot flashes.
Fezolinetant, sold as Veozah, was approved by the Food and Drug Administration for hot flashes in 2023, while elinzanetant, sold as Lynkuet, received approval in 2025.
-
Question 8 · Single choice
Choose one answer.
What do the newer nonhormonal medicines block?
Return to the passage, recording or visual- Hormone receptors in the uterine lining
- Chemical messengers involved in temperature and sleep regulation
- Blood vessels associated with pulmonary embolism
- Enzymes responsible for estrogen production
Check answers and explanations
- Answer
- Chemical messengers involved in temperature and sleep regulation
Their stated mechanism involves blocking messengers regulating temperature and sleep-wake cycles.
These medicines work by blocking chemical messengers involved in regulating body temperature and sleep-wake cycles.
What to review next
Listen again to difficult sections, then open the transcript to check what you heard. Repeat a useful phrase aloud and try the recording once more without the text.
A focused practice result shows how you did on these tasks. Use several activities across skills to decide what to study next; one practice score does not certify an overall CEFR level.
Before you practise: a worked example
Listen for the final information, especially when a speaker corrects or changes an earlier statement.
Example transcript: “Let’s meet at five — actually, half past five would be better.” What is the final suggested time?
The final suggested time is 5:30. Actually signals a correction; the first time is replaced by the later suggestion.
This teaching example is separate from the scored questions. After your test, compare any mistakes with the explanation and revisit the topic before trying again.